Janux Therapeutics Inc (JANX)
N/A x N/A N/A x N/A
Post-market by (Cboe BZX)
29.94 -0.49 (-1.61%) 03/21/25 [NASDAQ]
N/A x N/A N/A x N/A
Post-market 29.94 unch (unch) 16:55 ET
for Fri, Mar 21st, 2025
Try Excel 
Watch
-
Add or delete the symbol from one or more Watchlists.
-
Create New Watchlist
This name already in use.
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2024 | 12-2023 | 12-2022 | 12-2021 | 12-2020 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 430,605 | 19,205 | 51,426 | 35,582 | 7,813 |
| Marketable Securities | 594,568 | 324,823 | 275,590 | 339,383 | N/A |
| Receivables | N/A | N/A | N/A | N/A | 8,000 |
| TOTAL | $1,033,666 | $349,241 | $332,439 | $377,019 | $16,062 |
| Non-Current Assets | |||||
| PPE Net | 4,864 | 7,003 | 7,086 | 1,412 | 155 |
| Other Non-Current Assets | 22,986 | 24,163 | 24,485 | 1,393 | 0 |
| TOTAL | $27,850 | $31,166 | $31,571 | $2,805 | $155 |
| Total Assets | $1,061,516 | $380,407 | $364,010 | $379,824 | $16,217 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 4,026 | 2,424 | 2,159 | 2,458 | 428 |
| Accrued Expenses | 11,684 | 7,387 | 8,179 | 3,779 | 751 |
| Other current liabilities | N/A | N/A | N/A | 1,203 | 52 |
| TOTAL | $17,459 | $13,033 | $16,507 | $12,797 | $3,181 |
| Non-Current Liabilities | |||||
| Deferred Revenues | N/A | 1,705 | 5,406 | 5,163 | 1,950 |
| aiOther Non-Current Liabilities | 21,276 | 23,025 | 24,542 | 0 | 0 |
| TOTAL | $21,276 | $23,025 | $26,763 | $700 | $6,050 |
| Total Liabilities | $38,735 | $36,058 | $43,270 | $13,497 | $9,231 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 59,105 | 51,660 | 41,833 | 41,623 | N/A |
| Common Shares | 59 | 46 | 42 | 41 | 1 |
| Retained earnings | -237,757 | -168,763 | -110,470 | -47,411 | -14,739 |
| Other shareholders' equity | 2,163 | 665 | -1,535 | -270 | 21,624 |
| TOTAL | $1,022,781 | $344,349 | $320,740 | $366,327 | $6,986 |
| Total Liabilities And Equity | $1,061,516 | $380,407 | $364,010 | $379,824 | $16,217 |